CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share on its common stock, payable on July 31, 2026 to shareholders of record on July 10, 2026. The move follows a strategic transaction with Apotex Health, under which Cumberland received $100 million in cash plus up to $11 million in additional potential payments.

The board also authorized an open-market share repurchase program of up to $5 million and noted that several directors plan new share purchase plans. Cumberland will focus resources on developing ifetroban across multiple Phase II programs targeting rare and serious diseases, while retaining significant liquidity and its majority stake in Cumberland Emerging Technologies.

Positive

• $1.50 per share special cash dividend payable July 31, 2026
• Strategic transaction delivered $100 million cash plus up to $11 million additional
• Authorized open-market share repurchase program up to $5 million
• Board members plan additional share purchases, signaling insider alignment
• Retains majority ownership in Cumberland Emerging Technologies and late-stage pipeline
• Multiple Phase II ifetroban programs with prior favorable safety and designation signals

Negative

• None.

News Explained

Existing common holders receive a declared per-share cash distribution, while the repurchase remains an authorized ceiling rather than a reported completed purchase.

In its July 13, 2026 release, Cumberland Pharmaceuticals said its board authorized and declared a special cash dividend of $1.50 per common share, payable on July 31, 2026 to holders of record on July 10, 2026. This creates a declared cash payment to eligible common holders, although the release does not state a total dollar payout.

The board also authorized an open-market share-repurchase program with a ceiling of $5 million over time; the disclosure describes an authorization, not completed repurchases. The release therefore combines a per-share distribution with a maximum-sized buyback program, while the amount of any actual repurchases remains unreported.

The company separately reports that its Apotex transaction has closed, producing $100 million in cash at closing, with up to $11 million of additional payments expected for product inventory and transitional support services.

News Market Reaction – CPIX

+10.29% 7.0x vol

14 alerts

+10.29% Session close to close

+15.8% Peak Tracked

-3.9% Trough Tracked

$90.50M Market Cap

7.0x Rel. Volume

In the Jul 13 session, CPIX gained 10.29%, reflecting a significant positive market reaction. Argus tracked a peak move of +15.8% during that session. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 7.0x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Record Date is July 10, 2026 & Payment Date is July 31,2026

Corporate and Insider Share Purchase Initiatives to Continue

NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 10, 2026.

Cumberland previously announced the closing of a Strategic Transaction with Apotex Health, resulting in the integration of the U.S.-branded businesses. Cumberland received $100 million in cash at closing for its line of FDA-approved products. In addition, Cumberland expects to receive up to $11 million in additional payments associated with product inventory and transitional support services.

Following the closing of the Apotex transaction, an analysis by the company's tax advisors, along with refined financial projections, indicated greater net cash from the transaction than originally projected. Therefore, Cumberland's Board of Directors met to assess the Company's future cash needs and evaluate possible options for returning capital to shareholders. 

In addition to the special dividend, the Board authorized an open-market share repurchase program of up to $5 million in Cumberland shares over time. Several Board members will also be establishing new share purchase plans to increase their holdings in the Company.

"In keeping with our ongoing commitment to deliver value to our shareholders, we are issuing a special dividend following the strategic transaction, which treats all shareholders equally," said A,J. Kazimi, Cumberland's CEO. "After the payout of $1.50 per share, we believe the Company will still have significant liquidity and financial flexibility to fund our long-term product development efforts, with additional reserves available to address any new opportunities".

Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases:

• Duchenne Muscular Dystrophy Cardiomyopathy: 
  Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.
  
  
• Systemic Sclerosis: 
  Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone.
  
  
• Idiopathic Pulmonary Fibrosis: 
  A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S. Favorable interim safety findings have been announced, and the next milestone is the announcement of the efficacy results.
  
  
• Cancer Metastasis: 
  Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggest the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis. 

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.

For more information, please visit www.cumberlandpharma.com.

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-special-dividend-of-1-50-per-share-302823903.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What is the amount and payment date of Cumberland Pharmaceuticals (CPIX) 2026 special dividend?

Cumberland Pharmaceuticals declared a special dividend of $1.50 per share, payable on July 31, 2026. According to Cumberland Pharmaceuticals, shareholders must be on record as of July 10, 2026 to receive this cash distribution on the company’s common stock.

Why is Cumberland Pharmaceuticals (CPIX) issuing a $1.50 special dividend in 2026?

Cumberland is issuing the $1.50 per share special dividend following its strategic transaction with Apotex Health. According to Cumberland Pharmaceuticals, tax analysis and updated projections showed greater net cash than expected, enabling capital return while maintaining liquidity for long-term product development and future opportunities.

How does the Apotex Health transaction support Cumberland Pharmaceuticals (CPIX) dividend and buyback?

The Apotex Health transaction provided $100 million in cash at closing plus up to $11 million in additional payments. According to Cumberland Pharmaceuticals, higher-than-expected net cash from this deal allowed both the $1.50 special dividend and authorization of a $5 million share repurchase program.

What are the details of Cumberland Pharmaceuticals (CPIX) new share repurchase program?

Cumberland’s board authorized an open-market share repurchase program of up to $5 million in CPIX shares over time. According to Cumberland Pharmaceuticals, several board members also plan new personal share purchase plans, aiming to increase their holdings alongside this corporate capital return initiative.

What diseases is Cumberland Pharmaceuticals’ ifetroban targeting in its Phase II programs?

Ifetroban is being studied in Phase II programs for Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, idiopathic pulmonary fibrosis, and cancer metastasis. According to Cumberland Pharmaceuticals, these trials address serious rare and progressive diseases, with prior favorable safety data and multiple FDA designations in certain indications.

How might Cumberland Pharmaceuticals (CPIX) 2026 special dividend affect shareholders?

The 2026 special dividend provides immediate cash of $1.50 per share to eligible shareholders. According to Cumberland Pharmaceuticals, this capital return follows stronger-than-expected net proceeds from the Apotex transaction while the company expects to preserve significant liquidity to fund its ifetroban clinical development pipeline.